

UK MYELOMA FORUM
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

UK MYELOMA FORUM

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Prof G Cook
Dr J Ashcroft
Dr N Rabin
Dr G Pratt
Dr M Kaiser
Dr K Ramasamy
Dr S Stern
Dr R Popat
Dr M Jenner
S Henshaw
Dr S Lawless
Dr R Soutar
Dr R Hall
Dr J Sive
Dr S Lawson
Dr C Bygrave

Charity number

1082702

Principal address

Royal Bournemouth Hospital
Castle Lane East
Bournemouth
BH7 7DW

Independent examiner

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

Bankers

Coutts & Co
440 Strand
London
WC2R 0QS

UK MYELOMA FORUM

CONTENTS

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the accounts	10 - 17

Trustees' Annual Report for the period						
From	Period start date			To	Period end date	
	Day	Month	Year		Day	Month
	1	April	2021		31	March 2022

Section A Reference and administration details

Charity name	UK Myeloma Forum
Other names charity is known by	UKMF
Registered charity number (if any)	1082702
Charity's principal address	Royal Bournemouth Hospital
	Castle Lane East
	Bournemouth
Postcode	BH7 7DW

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr John Ashcroft (Leeds, Mid Yorks)	Chair / Board member	Chair November 2019 - November 2021	
2.	Dr Rachel Hall (Bournemouth)	Board Member/Treasurer	November 2019 -November 2023	
3.	Prof Gordon Cook (Leeds)	Past Chair/HTA lead	November 2019- November 2021	
4.	Dr Neil Rabin (London)	Chair Elect	January 2019 - November 2021	
5.	Prof Guy Pratt (Birmingham)	Secretary	November 2002-November 2023	
6.	Dr Martin Kaiser (London)	Board member	January 2019 – January 2022	
7.	Dr Karthikeyan Ramasamy (Oxford)	Communications Lead	June 2020 - June 2022	
8.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 202 - June 2023	
9.	Dr Rakesh Popat (London)	Science Lead	November 2018 - November 2021	
10.	Dr Matthew Jenner (Southampton)	Board member	March 2019 - March 2022	

11.	Dr Jonathan Sive (London)	Board member	January 2020 -January 2023	
12.	Sarah Henshaw (Nottingham)	Myeloma Nurse Lead	November 2018 -November 2021	
13.	Dr Ceri Bygrave (Cardiff)	Wales Representative (Invited Board member)	November 2015 -November 2021	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2018 -January 2024	
15.	Dr Richard Soutar (Glasgow)	Scotland Representative (Invited Board member)	January 2018 -January 2024	
16.	Dr Michelle Lawson (Sheffield)	Board member	January 2020 – January 2023	
17.	Laura Kerby (Myeloma UK)	Patient/Charity Representative	January 2018-November 2021	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Joel Courts, HW Fisher LLP	Acre House 11-15 William Road London NW1 3ER
Bankers	Coutts & Co	440 Strand London WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association
Trustee selection methods (eg. appointed by, elected by)	Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The Charity's objects ("the objects") are

1. The advancement of education of the general public, in particular in the treatment of those suffering from myeloma and related disorders, through the promotion and conduct of research and the publication and dissemination of all useful results of such research.
2. The relief of persons suffering from myeloma and related disorders, in particular by
 - a) the development and provision of policy guidelines for their treatment
 - b) promoting an understanding of the issues relating to myeloma and related disorders by encouraging communication and the exchange of information between research groups and healthcare professionals.

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMF had a further active year in pursuit of its charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held in 2021-2022; June 2021, November 2021 and March 2022.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue received for corporate sponsorship contributed £121,320 (April 2021-March 2022). This re-enforces the support by pharma for the work that the UKMF undertakes.

The Autumn Day was held on 11th November 2021, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was 'Sequencing Therapy and Personalised Medicine in Myeloma' and featured Professor Faith Davies from NYU Grossman School of Medicine, New York. Prof. Davies presented the Michael Morley Lecture on 'My current approach to sequencing therapy in myeloma and how this can be refined with personalised therapy'.

The Spring Day was also a virtual meeting and was held on 16th March 2022. The theme for this meeting was the, 'Relapsed Myeloma and the Impact of Covid-19'. The plenary lecture was given by Dr Vincent Rajkumar from the Mayo Clinic in Rochester. His talk was entitled, 'How I treat relapsed myeloma: a global perspective'.

A total of eight travel grants for scientific conferences were awarded in 2021 to winning abstracts. Three bursaries of £140 each to EHA Virtual in June 2021. The EHA abstracts were presented at the Autumn Day in November 2021. Five bursaries of £450 covered the registration fee for ASH (American Society of Haematology Annual Meeting). The ASH abstracts were presented at the Spring Day in March 2022. A review of ASH was produced in the e-newsletter.

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

The annual meetings

Producing two successful and well attended educational hybrid meetings in November 2021 and March 2022. For full programme details, please refer to the section above and the UKMF website.

Travel grants for scientific meetings

The UKMF awarded a number of bursaries in 2021-22 at EHA Virtual in June 2021 and ASH Atlanta (American Society of Haematology Meeting) in December 2021.

Advocacy

The UKMF members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMF also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMF Guidelines Group, Chaired by Dr Simon Stern remained active despite the difficulties caused by the Covid-19 pandemic, good progress had been made on the development of 2 new separate sets of guidelines on the management of both newly diagnosed and relapsed multiple myeloma.

A full first draft of the newly diagnosed guidelines had been reviewed by the BSH Haemato-oncology Task Force and BSH Guidelines Committee. A first full draft of the relapsed guidelines was near completion.

In addition, writing groups had been set up with a view to producing Good Practice Papers (GPPs) on the diagnosis and management of both MGUS and MGRS.

Section D

Achievements and performance

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group meet virtually twice a year with one face to face meeting planned at the Wellcome Collection on 15th June 22.

Myeloma Nurse Group

The nurse group, Chaired by Sarah Henshaw plan to do a best practice guide for Peripheral Neuropathy and an audit of the positive aspect that have come out of Covid for nurses in hospitals. The group are also working with Myeloma UK to update and review the nurse guidelines.

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Andrea Preston was newly established in 2021 and launched at the Spring Day in March 22. The Group will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMF work-plan, and aim to standardise clinical practice across the UK. There are 11 core members.

College of Myeloma (UK)

Created in 2019, the College of Myeloma (UK) consists of elected fellows representing those who have contributed significantly to the work of the UKMF and to patients with Myeloma through medical science, education and clinical care.

2021 fellows : Professor Mark Cook
Professor Graham Jackson
Dr Jenny Bird

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMF's policy on reserves is to maintain sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any

Income

Education Grants from Corporate Sponsors contributed £121,320, April 2021 - March 2022.

The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMF and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum. See section D for further details).

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Administrative Secretary, accountants' fees, employer's liability insurance and teleconferencing).

ethical investment policy adopted.

Spring and Autumn educational meetings in the 21-22 year at £22,515.

Travel bursaries to ASH 2021 = £450 x 5 each

Travel bursaries to EHA 2021= £140 x 3 each

Website redevelopment deposit = £5,400

Reserves

The UKMF's free reserves remain sound as of 31st March 2022 and were approximately £185,963.

Section F

Other optional information

--

Section G

Declaration

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)

R Hall

Full name(s)

Dr Rachel Hall

Position (eg Secretary, Chair, etc)

Treasurer

Date

14 Mar 2023

UK MYELOMA FORUM

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF UK MYELOMA FORUM

I report to the trustees on my examination of the financial statements of UK Myeloma Forum (the charity) for the year ended 31 March 2022.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Joel Courts

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

14 Mar 2023

Dated:

UK MYELOMA FORUM

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2022

		Unrestricted funds general 2022	Unrestricted funds designated 2022	Total 2022	Unrestricted funds general 2021	Unrestricted funds designated 2021	Total 2021
	Notes	£	£	£	£	£	£
Income from:							
Donations and legacies	3	121,320	-	121,320	133,560	-	133,560
Investments	4	10	4,275	4,285	29	4,334	4,363
Total income		121,330	4,275	125,605	133,589	4,334	137,923
Expenditure on:							
Raising funds	5	-	1,633	1,633	-	1,436	1,436
Charitable activities	6	72,984	-	72,984	53,329	-	53,329
Total resources expended		72,984	1,633	74,617	53,329	1,436	54,765
Net gains/(losses) on investments	11	-	3,863	3,863	-	41,166	41,166
Net movement in funds		48,346	6,505	54,851	80,260	44,064	124,324
Fund balances at 1 April 2021		137,617	277,212	414,829	57,357	233,148	290,505
Fund balances at 31 March 2022		185,963	283,717	469,680	137,617	277,212	414,829

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

UK MYELOMA FORUM

BALANCE SHEET

AS AT 31 MARCH 2022

		2022		2021	
	Notes	£	£	£	£
Fixed assets					
Investments	12		224,717		218,212
Current assets					
Debtors	13	8,199		283	
Cash at bank and in hand		248,241		202,392	
		<u>256,440</u>		<u>202,675</u>	
Creditors: amounts falling due within one year	14	<u>(11,477)</u>		<u>(6,058)</u>	
Net current assets			244,963		196,617
Total assets less current liabilities			<u>469,680</u>		<u>414,829</u>
Income funds					
Unrestricted funds - designated	15		283,717		277,212
Unrestricted funds - general			185,963		137,617
			<u>469,680</u>		<u>414,829</u>

14 Mar 2023

The financial statements were approved by the Trustees on



.....

Dr Rachel Hall

Trustee

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

Charity information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Dorset, BH14 9QN

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Interest receivable on fixed interest securities and cash deposits is accrued.

1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of generating funds consist of investment management fees.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the one charitable activity in the statement of financial activities.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

(Continued)

1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.7 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any critical accounting estimates or judgements applied in the preparation of the financial statements.

3 Donations and legacies

	Unrestricted funds general 2022 £	Unrestricted funds general 2021 £
Donations	121,320	133,560

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

4 Investments

	Unrestricted funds general 2022 £	Unrestricted funds designated 2022 £	Total 2022 £	Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £
Investment income	10	4,275	4,285	29	4,334	4,363

5 Raising funds

	2022 £	2021 £
Investment management fees	1,633	1,436
	1,633	1,436

6 Charitable activities

	2022 £	2021 £
Forum expenses	34,177	17,217
Management fees	144	650
	34,321	17,867
Grant funding of activities (see note 7)	2,670	1,050
Share of support costs (see note 8)	29,819	27,932
Share of governance costs (see note 8)	6,174	6,480
	72,984	53,329
Analysis by fund		
Unrestricted funds - general	72,984	53,329

7 Grants payable

	2022 £	2021 £
Grants to individuals	2,670	1,050
	2,670	1,050

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

8 Support costs

	Support costs	Governance costs	2022	Support costs	Governance costs	2021
	£	£	£	£	£	£
Staff costs	29,819	-	29,819	27,932	-	27,932
Accountancy	-	6,174	6,174	-	6,480	6,480
	<u>29,819</u>	<u>6,174</u>	<u>35,993</u>	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>
Analysed between						
Charitable activities	<u>29,819</u>	<u>6,174</u>	<u>35,993</u>	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>

Governance costs includes payments to the independent examiner of £2,640 (2021: £2,640) for independent examination fees and £3,534 (2021: £3,840) for accountancy services.

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year. During the year, travelling expenses of £1,919 (2021: Nil) were reimbursed to 9 trustees.

10 Employees

The average monthly number employees during the year was.

	2022 Number	2021 Number
Administration	<u>1</u>	<u>1</u>
Employment costs	2022	2021
	£	£
Wages and salaries	29,151	27,312
Other pension costs	668	620
	<u>29,819</u>	<u>27,932</u>

Key management personnel are the trustees and they received no remuneration during the current or prior year.

There were no employees whose annual remuneration was £60,000 or more.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

11 Net gains/(losses) on investments

	Unrestricted funds designated 2022 £	Unrestricted funds designated 2021 £
Revaluation of investments	3,739	38,443
Gain/(loss) on sale of investments	124	2,723
	<u>3,863</u>	<u>41,166</u>

12 Fixed asset investments

	Listed investments £	Cash in portfolio £	Total £
Cost or valuation			
At 1 April 2021	201,862	16,350	218,212
Additions	22,269	(22,269)	-
Valuation changes	3,739	-	3,739
Dividend and interest received	-	4,275	4,275
Management fee	-	(1,633)	(1,633)
Disposals	(19,147)	19,271	124
	<u>208,723</u>	<u>15,994</u>	<u>224,717</u>
At 31 March 2022	208,723	15,994	224,717
Carrying amount			
At 31 March 2022	<u>208,723</u>	<u>15,994</u>	<u>224,717</u>
At 31 March 2021	<u>201,862</u>	<u>16,350</u>	<u>218,212</u>

13 Debtors

	2022 £	2021 £
Amounts falling due within one year:		
Other debtors	2,799	283
Prepayments	5,400	-
	<u>8,199</u>	<u>283</u>

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

14 Creditors: amounts falling due within one year

	2022	2021
	£	£
Other creditors	4,428	178
Accruals	7,049	5,880
	<hr/>	<hr/>
	11,477	6,058
	<hr/>	<hr/>

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

15 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds					Movement in funds				
	Balance at 1 April 2020	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 1 April 2021	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 31 March 2022	
	£	£	£	£	£	£	£	£	£	
Michael Morley Investment Fund	233,148	4,334	(1,436)	41,166	277,212	4,275	(1,633)	3,863	283,717	
	<u>233,148</u>	<u>4,334</u>	<u>(1,436)</u>	<u>41,166</u>	<u>277,212</u>	<u>4,275</u>	<u>(1,633)</u>	<u>3,863</u>	<u>283,717</u>	

The designated fund is used to hold the Charity's investments and generate income.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

16 Analysis of net assets between funds

	Unrestricted 2022 £	Designated 2022 £	Total 2022 £	Unrestricted 2021 £	Designated 2021 £	Total 2021 £
Fund balances at 31 March 2022 are represented by:						
Investments	-	224,717	224,717	-	218,212	218,212
Current assets/(liabilities)	185,963	59,000	244,963	137,617	59,000	196,617
	<u>185,963</u>	<u>283,717</u>	<u>469,680</u>	<u>137,617</u>	<u>277,212</u>	<u>414,829</u>

17 Analysis of changes in net funds

The charity had no debt during the year.

18 Related party transactions

There were no disclosable related party transactions during the year (2021 - none).